BIOSIMILARS AND ORIGINATORS HAVE SIMILAR SAFETY PROFILES

摘要

Although biosimilars have been available in the European Union for more than ten years, their uptake in routine care across the region has been highly variable. A cross-sectional analysis was conducted on publicly available information on biosimilars and their originators, filed for regulatory purposes at European Medicines Agency level. A total of 19 biosimilars and 6 originators were included.